Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections

Core Insights - Barinthus Biotherapeutics plc is prioritizing the development of VTP-300 for chronic Hepatitis B (CHB) and VTP-1000 for celiac disease, while completing the ongoing Phase 1 trial of VTP-850 for prostate cancer [1][2][5] - The company plans to restructure its operations, which will include a workforce reduction of approximately 25% and an extension of its cash runway into the second quarter of 2026 [2][4] Pipeline Focus - VTP-300 is designed as a potential component of a functional cure for chronic HBV infection, with recent Phase 2 interim data showing its ability to significantly reduce and maintain Hepatitis B surface antigen (HBsAg) levels [5][9] - VTP-1000 aims to treat celiac disease by balancing the immune response through the induction of gluten-specific T regulatory cells, with a Phase 1 clinical trial expected to start in the third quarter of 2024 [5][9] Company Overview - Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company focused on T cell immunotherapeutic candidates for chronic infectious diseases, autoimmunity, and cancer [3][9] - The company utilizes three proprietary platform technologies: ChAdOx, MVA, and SNAP, to advance its product candidates [3]